Skip to main content

Defecatory Dysfunction

Defecatory dysfunction — also termed functional defecation disorder, dyssynergic defecation, outlet dysfunction, or obstructed defecation — is the inability to satisfactorily expel stool because of inadequate rectal propulsive forces, increased outlet resistance, or both.[1][2] It is the most common cause of medically refractory chronic constipation and is underrecognized because the symptoms overlap entirely with those of slow-transit and normal-transit constipation. The diagnostic decision point is not symptomatic — it is physiologic, made on anorectal manometry with balloon expulsion, with defecography as a second-line test.[1][3]

See the subsection landing for how defecatory dysfunction sits alongside chronic constipation and fecal incontinence.

Epidemiology​

For generic chronic-constipation prevalence, see Chronic Constipation — Epidemiology. The DD-specific numbers that matter:

  • Functional defecation disorders account for 33–50% of chronic-constipation referrals to pelvic-floor testing.[1][4]
  • About 37% of chronic-constipation patients who undergo anorectal physiology testing have dyssynergic defecation.[5]
  • Up to 50% of patients with defecatory disorders also have delayed colonic transit, which may be secondary to pelvic-floor dysfunction rather than a primary motility disease.[2]

Pathophysiology​

Three mechanisms, usually in combination:[1][2]

  1. Inadequate rectal propulsion — insufficient intra-abdominal/rectal pressure during attempted defecation
  2. Increased outlet resistance — paradoxical contraction or failure of relaxation of the external anal sphincter and/or puborectalis during defecation; high anal resting pressure ("anismus")
  3. Structural / sensory contributors — rectocele, rectal intussusception, excessive perineal descent, and rectal hyposensitivity that reduces the urge to defecate

Defecatory dysfunction is best understood as an acquired behavioral disorder — maladaptive coordination learned after pain, trauma, or chronically deferred defecation. Over time, chronic straining weakens the pelvic floor and produces secondary excessive perineal descent, rectal intussusception, pudendal neuropathy, and solitary rectal ulcer — which in turn worsen evacuation and can produce overflow fecal incontinence.[1][2][6]

Classification​

Rome IV — Functional Defecation Disorders​

Diagnosis requires ≥2 constipation symptoms (Rome IV) — straining, hard stools, incomplete evacuation, anorectal blockage, manual maneuvers, or <3 spontaneous bowel movements weekly — plus objective evidence of impaired evacuation on two of three tests (anorectal manometry, balloon expulsion, defecography).[7]

SubtypeDefinition
Dyssynergic defecationParadoxical contraction or inadequate relaxation of the pelvic floor muscles during attempted defecation with adequate propulsive force
Inadequate defecatory propulsionInsufficient propulsive force during attempted defecation, with or without sphincter / pelvic-floor dyssynergia

High-resolution manometry patterns of dyssynergia​

Four patterns, all clinically actionable:[8]

TypeRectal pushAnal response
IAdequateParadoxical contraction
IIInadequateParadoxical contraction
IIIAdequateImpaired / incomplete relaxation
IVInadequateImpaired relaxation

London Protocol framework​

The 2020 London consensus reorganizes anorectal pathophysiology on manometry + BET into: (1) rectoanal inhibitory reflex disorders (absent in Hirschsprung disease); (2) anal tone and contractility disorders; (3) rectoanal coordination disorders (the dyssynergia group); (4) rectal sensory disorders (hypersensitivity vs hyposensitivity).[3]

Clinical Presentation​

Symptoms are indistinguishable from other constipation types — hence the diagnostic reliance on physiology. Classic features:[1]

  • Excessive straining
  • Sensation of anorectal blockage
  • Manual maneuvers (digitation, perineal or vaginal splinting)
  • Sensation of incomplete evacuation
  • Enema or suppository dependence
  • Hard stools and reduced frequency

Digital rectal exam​

The underused, high-yield bedside maneuver. Accurate DRE for dyssynergia is ~75% sensitive, 87% specific against manometry.[1]

Assess at rest, with squeeze, and during simulated defecation:

  • Anal tone at rest
  • Voluntary squeeze (external sphincter + puborectalis integrity)
  • Push / bear down — the sphincter should relax and the puborectalis should release the anorectal angle; paradoxical contraction or no relaxation suggests dyssynergia
  • Palpable stool, rectocele (push anteriorly), excessive perineal descent, prolapse on strain

Diagnostic Evaluation​

The first-line combination is anorectal manometry + balloon expulsion test; defecography is reserved for the discordant case.[1][2]

TestWhat it measuresUse
Balloon expulsion test (BET)Time to expel a 50-mL water-filled rectal balloon; prolonged = ≥ 1 minSimple, specific screen; normal BET is strong evidence against functional outlet obstruction[3]
High-resolution anorectal manometry (HRM)Resting / squeeze / push pressures, rectoanal inhibitory reflex, rectal sensationClassifies dyssynergia pattern (I–IV); quantifies the rectoanal gradient during push[3]
Defecography (fluoroscopic or MR)Structural anatomy and functional evacuation — rectocele trapping, intussusception, enterocele, perineal descentSecond-line when ARM/BET discordant, or when structural disease suspected[9]

Pragmatic rules:[10]

  • Both BET and rectoanal gradient abnormal → ~75% probability of impaired evacuation (definite defecatory dysfunction)
  • One abnormal → ~45% probability (probable)
  • Both normal → ~14% probability — look elsewhere
  • Rome IV requires ≥ 2 abnormal tests to confirm the diagnosis.[7]

Defecography specifically differentiates rectocele (anterior wall), enterocele (cul-de-sac hernia), intussusception, and measures perineal descent — the information that drives the decision between biofeedback alone, rectocele repair, or rectopexy.[11]

Management​

First: lifestyle and bowel-management baseline​

Before pursuing biofeedback, confirm that bowel-management basics are in place:[1][12]

  • Hydration and stool-form optimization (Bristol target ~4)
  • Routine post-meal toileting to exploit the gastrocolonic reflex; footstool for squat posture
  • Stopping constipating medications where possible
  • Adequate trials of fiber, osmotic laxatives, and stimulant rescue therapy

The full pharmacologic algorithm — AGA/ACG 2023 stepwise management, secretagogues, 5-HT4 agonists — is covered in Chronic Constipation. The DD-specific point: up to 50% of defecatory-dysfunction patients have coexistent slow transit, but this does not change the order of operations. Treat the outlet first — slow transit often improves once evacuation is restored, and escalating laxatives or secretagogues in the setting of unaddressed dyssynergia is low yield.[1][2]

Second: anorectal biofeedback therapy (the cornerstone)​

For dyssynergic defecation, biofeedback is first-line and definitive treatment, not an adjunct.[1][5][13]

Goals:

  • Coordinate abdominal push with pelvic-floor / sphincter relaxation (not simultaneous contraction)
  • Improve diaphragmatic push mechanics
  • Rectal sensory retraining for hyposensitivity
  • Balloon-expulsion retraining

Delivery: EMG or manometry-guided feedback, 4–6 sessions over weeks to months. EMG biofeedback is superior to non-EMG modalities (OR 6.74).[5]

Evidence:

  • ~80% symptomatic response in patients with confirmed dyssynergia (vs ~22% with laxatives + lifestyle alone) — relative risk ~3.65[5]
  • 55–82% of responders maintain improvement long-term[5]
  • Plain pelvic-floor physical therapy without biofeedback is not effective for defecatory disorders — this is a specific intervention, not generic PFPT[1]

Predictors of response:[14] absence of baseline manual maneuvers, reported awareness that "anal muscles are causing the straining," and demonstrable coordination deficit on augmented DRE.

Third: botulinum toxin​

For biofeedback non-responders with a nonrelaxing puborectalis:[1][15]

  • Onabotulinum toxin A 100 U injected into the puborectalis ± external anal sphincter, typically at the 3 and 9 o'clock positions (transanal approach)
  • Symptom response is highly variable across studies (29–100%) and is temporary (≤ 3 months)
  • Adverse event rate ~14%, principally flatus and fecal incontinence
  • Combination with post-injection biofeedback may extend durability
  • The overall evidence base is low quality (heterogeneous doses, outcomes, and designs)

Surgical considerations​

Surgery addresses structural contributors; it does not fix dyssynergia.[1][16]

PathologySurgical optionKey caveat
Rectocele — symptomatic, >5 cm, with contrast trapping on defecography and evacuation failureTransvaginal posterior repair (Grade A over transanal); ~73% short-term successOnly after addressing any coexisting dyssynergia — otherwise repair fails functionally
Rectal intussusceptionVentral mesh rectopexy, DelormeAnatomy may be corrected without symptom improvement
Full-thickness rectal prolapseAbdominal rectopexy ± resectionReferral to colorectal surgery
STARR (stapled transanal rectal resection)Not recommended (ASCRS 2024)High complication rate — bleeding, pain, incontinence, fistula, perforation
Sacral neuromodulation for constipationNot recommendedThree RCTs show no benefit; 61% device-related adverse-event rate at 5 years

Refractory defecatory dysfunction​

Before labeling a patient "refractory," the AGA clinical-practice update (2026) requires:[17]

  1. Anorectal manometry with balloon expulsion completed
  2. A documented course of pelvic-floor biofeedback therapy
  3. Two of three abnormal tests (gradient on ARM, prolonged BET, inadequate evacuation on defecography) confirming the diagnosis

Only after this can the patient be meaningfully categorized as refractory and considered for botulinum toxin, surgical referral for structural disease, or multi-disciplinary GI-motility work-up.

Pearls for the Reconstructive Pelvic Surgeon​

  • A careful DRE with simulated defecation is the single most informative office maneuver. Do it before offering any posterior-compartment surgery.
  • If a patient with a rectocele also has dyssynergia, the dyssynergia is the disease — fix it first. Rectocele repair in an unaddressed dyssynergic patient produces a technically intact repair and an unhappy patient.
  • "Pelvic floor therapy" is not a monolith. Anorectal biofeedback is the intervention that works for defecatory dysfunction; generic PFPT is not a substitute.[1]
  • Slow transit often improves after the outlet is restored. Resist the urge to escalate prokinetics before the outlet has been properly addressed.
  • Overflow fecal incontinence looks like an FI problem but is a defecatory-dysfunction problem. See Fecal Incontinence for the phenotype split and management.

See Also​

References​

1. Wald A, Bharucha AE, Limketkai B, et al. "ACG Clinical Guidelines: Management of Benign Anorectal Disorders." Am J Gastroenterol. 2021;116(10):1987-2008. doi:10.14309/ajg.0000000000001507

2. Bharucha AE, Lacy BE. "Mechanisms, Evaluation, and Management of Chronic Constipation." Gastroenterology. 2020;158(5):1232-1249.e3. doi:10.1053/j.gastro.2019.12.034

3. Rao SSC, Bharucha AE, Carrington EV, et al. "Anorectal Disorders." Gastroenterology. 2026. doi:10.1053/j.gastro.2026.01.037

4. Sadler K, Arnold F, Dean S. "Chronic Constipation in Adults." Am Fam Physician. 2022;106(3):299-306.

5. Skardoon GR, Khera AJ, Emmanuel AV, Burgell RE. "Dyssynergic Defaecation and Biofeedback Therapy in the Pathophysiology and Management of Functional Constipation." Aliment Pharmacol Ther. 2017;46(4):410-423. doi:10.1111/apt.14174

6. Heitmann PT, Vollebregt PF, Knowles CH, et al. "Understanding the Physiology of Human Defaecation and Disorders of Continence and Evacuation." Nat Rev Gastroenterol Hepatol. 2021;18(11):751-769. doi:10.1038/s41575-021-00487-5

7. Rao SS, Bharucha AE, Chiarioni G, et al. "Functional Anorectal Disorders." Gastroenterology. 2016. doi:10.1053/j.gastro.2016.02.009

8. Lalwani N, El Sayed RF, Kamath A, et al. "Imaging and Clinical Assessment of Functional Defecatory Disorders With Emphasis on Defecography." Abdom Radiol (NY). 2021;46(4):1323-1333. doi:10.1007/s00261-019-02142-9

9. Khatri G, Bhosale PR, Robbins JB, et al. "ACR Appropriateness Criteria® Pelvic Floor Dysfunction in Females." J Am Coll Radiol. 2022;19(5S):S137-S155. doi:10.1016/j.jacr.2022.02.016

10. Blackett JW, Gautam M, Mishra R, et al. "Comparison of Anorectal Manometry, Rectal Balloon Expulsion Test, and Defecography for Diagnosing Defecatory Disorders." Gastroenterology. 2022;163(6):1582-1592.e2. doi:10.1053/j.gastro.2022.08.034

11. Zoabi N, Zelikovich D, Kanani F, et al. "Integrating Anorectal Manometry, Balloon Expulsion and Defecography: Insights Into Diagnosing Pelvic Floor Dysfunction." Am J Physiol Gastrointest Liver Physiol. 2025. doi:10.1152/ajpgi.00100.2025

12. Chang L, Chey WD, Imdad A, et al. "AGA–ACG Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation." Gastroenterology. 2023;164(7):1086-1106. doi:10.1053/j.gastro.2023.03.214

13. Lee HJ, Jung KW, Myung SJ. "Technique of Functional and Motility Test: How to Perform Biofeedback for Constipation and Fecal Incontinence." J Neurogastroenterol Motil. 2013;19(4):532-7. doi:10.5056/jnm.2013.19.4.532

14. Lambiase C, Bellini M, Whitehead WE, et al. "Biofeedback Efficacy for Outlet Dysfunction Constipation: Clinical Outcomes and Predictors of Response by a Limited Approach." Neurogastroenterol Motil. 2025;37(1):e14948. doi:10.1111/nmo.14948

15. Chaichanavichkij P, Vollebregt PF, Scott SM, Knowles CH. "Botulinum Toxin Type A for the Treatment of Dyssynergic Defaecation in Adults: A Systematic Review." Colorectal Dis. 2020;22(12):1832-1841. doi:10.1111/codi.15120

16. Alavi K, Thorsen AJ, Fang SH, et al. "ASCRS Clinical Practice Guidelines for the Evaluation and Management of Chronic Constipation." Dis Colon Rectum. 2024;67(10):1244-1257. doi:10.1097/DCR.0000000000003430

17. Staller K, Neshatian L, Lembo A, Bharucha AE. "AGA Clinical Practice Update on Evaluation and Management of Refractory Constipation: Expert Review." Clin Gastroenterol Hepatol. 2026;24(2):296-305. doi:10.1016/j.cgh.2025.09.031